Sai Parenterals IPO to Open on March 24: Price Band, Offer Size, and Key Details Explained

Pharmaceutical company Sai Parenterals is set to launch its initial public offering (IPO) on March 24, aiming to raise ₹409 crore. With a mix of fresh issue and offer-for-sale, the IPO is expected to attract investor attention amid growing activity in India’s primary market.

Sai Parenterals IPO: Key Dates and Offer Details

Sai Parenterals will open its ₹409 crore IPO for public subscription on March 24, marking its debut in the capital markets. The issue will remain open until March 27, giving investors a four-day window to apply.

The company has fixed a price band of ₹372–₹392 per share, valuing the firm at approximately ₹1,732 crore at the upper end. Prior to the public issue, the anchor investor portion will open for bidding on March 23.

Following the closure of the issue, the allotment of shares is expected to be finalised by March 30. The company is likely to list on stock exchanges on April 2.

This IPO will be among the key mainboard listings next week, alongside offerings from Amir Chand Jagdish Kumar Exports and Central Mine Planning and Design Institute.

Breakdown of Issue Size: Fresh Issue and OFS

The ₹409 crore IPO comprises two components—a fresh issue of equity shares and an offer-for-sale (OFS).

The company plans to raise up to ₹285 crore through the issuance of new shares. These funds will be utilised for business expansion, debt reduction, and other corporate purposes.

Additionally, existing shareholders will offload around 31.57 lakh shares through the OFS route. Prominent investors participating in the OFS include Vikasa India EIF I Fund, Tilokchand Punamchand Ostwal, Devendra Chawla, Ashish Maheshwari, Padma Guntupalli, Bhautik Mukund Shah, and Nilesh Pravinchandra Doshi.

The OFS component allows early investors to partially exit while providing liquidity in the public market.

Utilisation of IPO Proceeds

Sai Parenterals has outlined a clear plan for deploying the funds raised through the fresh issue.

A significant portion—₹110.7 crore—will be allocated toward expanding and upgrading its manufacturing facilities. This investment is expected to enhance production capacity and improve operational efficiency.

The company will also invest ₹18 crore in establishing a new research and development (R&D) centre, reflecting its focus on innovation and product development.

Additionally, around ₹50 crore will be used to repay existing borrowings, helping to strengthen the company’s balance sheet. Another ₹33 crore has been earmarked for working capital requirements, while the remaining funds will be utilised for general corporate purposes.

This diversified allocation strategy highlights the company’s intent to support long-term growth while maintaining financial stability.

Business Overview: What Sai Parenterals Does

Founded in 2001, Sai Parenterals is a pharmaceutical firm engaged in the development, manufacturing, and marketing of a wide range of healthcare products.

The company operates across two primary segments. First, it manufactures and sells its own branded generic formulations. Second, it provides contract development and manufacturing organisation (CDMO) services for other pharmaceutical companies globally.

Its product portfolio spans multiple therapeutic categories, including cardiovascular diseases, neuropsychiatry, anti-diabetic care, respiratory health, antibiotics, gastroenterology, vitamins, minerals and supplements, analgesics, and dermatology.

The company offers its medicines in various dosage forms such as tablets, injections, and syrups, catering to diverse patient needs.

Manufacturing Capabilities and Global Presence

Sai Parenterals operates five manufacturing facilities located in Telangana and Andhra Pradesh, with a strong presence in Hyderabad—a key pharmaceutical hub in India. These facilities are equipped with modern infrastructure and comply with international quality standards, enabling the company to serve both domestic and international markets.

Its client base includes government agencies, hospitals, pharmaceutical companies, and large distributors across India and overseas.

In a strategic move to expand its global footprint, the company acquired Noumed Pharmaceuticals in November last year through its Singapore-based subsidiary. This acquisition strengthens its presence in the Australian market and enhances its capabilities in private-label and over-the-counter (OTC) pharmaceutical products.

Shareholding Pattern and Promoter Stake

Promoters of Sai Parenterals currently hold a 61.23 percent stake in the company. The remaining 38.77 percent is owned by public shareholders, including institutional investors such as Samarsh Capital Fund, AIG Direct, Agilis Partners, and Vikasa India.

The IPO will result in partial dilution of promoter holdings while broadening the shareholder base.

Financial Performance: Growth Trends and Profitability

On the financial front, Sai Parenterals has demonstrated steady growth in recent years. For the six-month period ending September 2025, the company reported a profit of ₹7.7 crore on revenue of ₹86.9 crore.

In the financial year ending March 2025, profit stood at ₹14.4 crore, reflecting a robust growth of 71.8 percent compared to ₹8.4 crore in the previous year. Revenue for FY25 increased by 6 percent to ₹163.1 crore, up from ₹153.8 crore in FY24.

While revenue growth has been moderate, the sharp increase in profitability indicates improved operational efficiency and cost management.

IPO Management and Merchant Banker

The IPO of Sai Parenterals is being managed by Arihant Capital Markets, which is acting as the sole merchant banker for the issue. The firm will oversee the IPO process, including pricing, allocation, and compliance with regulatory requirements.

Investment Outlook and Market Sentiment

The IPO comes at a time when India’s pharmaceutical sector continues to show resilience and growth potential, driven by increasing healthcare demand and global outsourcing opportunities. Investors may find Sai Parenterals attractive due to its diversified product portfolio, expanding manufacturing capabilities, and focus on R&D.

However, as with any IPO, potential investors should carefully evaluate factors such as market conditions, competition, regulatory environment, and financial performance before making investment decisions.

Conclusion

The upcoming IPO of Sai Parenterals represents an important milestone in the company’s growth journey. With a well-defined strategy for fund utilisation, expanding global presence, and improving financial performance, the company is positioning itself for the next phase of growth. As the subscription window opens on March 24, investor interest will likely hinge on the company’s long-term prospects and the overall sentiment in the primary market.